Freedom Broker lowers Omada Health stock price target to $20 from $26

Published 08/08/2025, 13:02
Freedom Broker lowers Omada Health stock price target to $20 from $26

Investing.com - Freedom Broker has lowered its price target on Omada Health Inc (NASDAQ:OMDA) to $20 from $26 while maintaining a Buy rating on the stock. The company, currently trading at $19.46 and commanding a market capitalization of $1.1 billion, has shown strong momentum with an impressive 12% gain over the past week. InvestingPro data reveals several additional key metrics that could impact investment decisions.

The adjustment follows Omada Health’s second-quarter results, which exceeded both the firm’s and consensus estimates, according to Freedom Broker analyst Gene Mannheimer.

Omada Health, which positions itself as a "between visit program provider" for common and costly chronic conditions, has demonstrated significant growth with a 50% increase in both members and revenue.

The company also narrowed its losses, nearly achieving break-even EBITDA approximately one year ahead of Freedom Broker’s projections.

Freedom Broker’s revised $20 price target is based on a 6x forward revenue multiple, which it notes is in line with select comparable companies but still represents a discount to competitor Hinge Health.

In other recent news, Omada Health has been the subject of multiple analyst initiations, reflecting a positive outlook on its stock. Freedom Broker initiated coverage with a Buy rating and a price target of $26.00, suggesting a potential upside of approximately 40% from current levels. Needham also started coverage with a Buy rating, setting a price target of $23.00, and highlighted Omada’s virtual-first care platform as a key strength. Evercore ISI joined in with an Outperform rating and a price target of $21.00, acknowledging the company’s service to over 679,000 members. Barclays (LON:BARC) initiated with an Overweight rating and a $21.00 price target, emphasizing the potential of Omada’s GLP-1 Care Track offerings. Morgan Stanley (NYSE:MS) also provided an Overweight rating with a $25.00 price target, noting the economic impact of chronic diseases that Omada addresses. These developments come after Omada Health’s initial public offering, which raised $150 million.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.